Quest Pharma, University of California deal

Quest PharmaTech received exclusive rights from the university to develop and market anti- prostate-specific antigen ( KLK3; PSA) IgE technology to treat cancer. The technology includes three pending patent applications that cover the use of IgE in development to treat PSA-expressing malignancies. Quest will make an upfront fee to the university, which is eligible for milestones and royalties. The acquisition is part of the company's focus on antibody-mediated cancer immunotherapy with both IgG and IgE products. The company could not be reached for details. ...